Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Apr 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying advanced thyroid cancer, specifically looking at how certain markers in the blood, called ctDNA, can help understand the disease better. While many patients with thyroid cancer are successfully treated, about 30% may see their cancer return after a long time, which can lead to more serious health issues. The researchers want to collect blood and tissue samples from participants to analyze these markers and see if they can track the cancer's evolution and response to treatments.

To participate in the study, you need to be 18 years or older and have specific types of thyroid cancer that are either resistant to standard treatments or newly diagnosed. This includes patients with a variety of thyroid cancer types, such as differentiated thyroid carcinoma and medullary thyroid cancer. Participants will undergo routine monitoring and treatment as recommended by their healthcare team and will need to provide informed consent for sample collection. If you join, you’ll be helping researchers understand better ways to manage advanced thyroid cancer, which could ultimately improve treatment options for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older. (all cohorts)
• • Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1)
• • Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2)
• • Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3)
• • Patients with newly diagnosed anaplastic thyroid cancer (cohort 4)
• • Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts)
• • Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts)
• • Ability to give informed consent for biological sample collection. (all cohorts)
• Exclusion Criteria:
• • Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection
• • Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ)
• • Pregnancy